Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

D'Angelo, G; Zweiker, D; Fierro, N; Marzi, A; Paglino, G; Gulletta, S; Matta, M; Melillo, F; Bisceglia, C; Limite, LR; Cireddu, M; Vergara, P; Bosica, F; Falasconi, G; Pannone, L; Brugliera, L; Oloriz, T; Sala, S; Radinovic, A; Baratto, F; Malatino, L; Peretto, G; Nakajima, K; Spartalis, MD; Frontera, A; Della, Bella, P; Mazzone, P.
Check the Need-Prevalence and Outcome after Transvenous Cardiac Implantable Electric Device Extraction without Reimplantation.
J Clin Med. 2021; 10(18): Doi: 10.3390/jcm10184043 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Führende Autor*innen der Med Uni Graz: Zweiker David
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: after transvenous lead extraction (TLE) of cardiac implantable electric devices (CIEDs), some patients may not benefit from device reimplantation. This study sought to analyse predictors and long-term outcome of patients after TLE with vs. without reimplantation in a high-volume centre. METHODS: all patients undergoing TLE at our centre between January 2010 and November 2015 were included into this analysis. RESULTS: a total of 223 patients (median age 70 years, 22.0% female) were included into the study. Cardiac resynchronization therapy-defibrillator (CRT-D) was the most common device (40.4%) followed by pacemaker (PM) (31.4%), implantable cardioverter-defibrillator (ICD) (26.9%), and cardiac resynchronization therapy-PM (CRT-P) (1.4%). TLE was performed due to infection (55.6%), malfunction (35.9%), system upgrade (6.7%) or other causes (1.8%). In 14.8%, no reimplantation was performed after TLE. At a median follow-up of 41 months, no preventable arrhythmia-related events were documented in the no-reimplantation group, but 11.8% received a new CIED after 17-84 months. While there was no difference in short-term survival, five-year survival was significantly lower in the no-reimplantation group (78.3% vs. 94.7%, p = 0.014). CONCLUSIONS: in patients undergoing TLE, a re-evaluation of the indication for reimplantation is safe and effective. Reimplantation was not related to preventable arrhythmia events, but all-cause survival was lower.
Find related publications in this database (Keywords): extraction; reimplantation; pacing; ICD; CRT